Passive Income Powerhouse Unveiled: The Ultimate Play!

The #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.

Find Out What It Is Right Here.

Michel Dahan Biography and Net Worth

COO of Akebia Therapeutics

Michel Dahan joined Akebia in 2013 and is Senior Vice President, Chief Operating Officer. Mr. Dahan previously served as our Chief Business Officer. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., most recently as Vice President, Commercial Development and Strategic Planning, and led global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France), and he completed an executive education program (PLD) at Harvard Business School.

What is Michel Dahan's net worth?: The estimated net worth of Michel Dahan is at least $746,248.10 as of May 25th, 2023. Mr. Dahan owns 574,037 shares of Akebia Therapeutics stock worth more than $746,248 as of June 7th. This net worth evaluation does not reflect any other investments that Mr. Dahan may own. Learn More about Michel Dahan's net worth.
What is Michel Dahan's salary?: As the COO of Akebia Therapeutics, Inc., Mr. Dahan earned a total compensation package of $2,012,127.00 in 2020. Mr. Dahan earned a salary of $461,055.00, stock awards of $679,868.00, options awards of $677,111.00, non-equity compensation of $184,300.00, and other compensation of $9,790.00. Learn More on Michel Dahan's salary.
How do I contact Michel Dahan?: The corporate mailing address for Mr. Dahan and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Michel Dahan's contact information.
Has Michel Dahan been buying or selling shares of Akebia Therapeutics?: During the last quarter, Michel Dahan has sold $116,483.16 in shares of Akebia Therapeutics stock. Most recently, Michel Dahan sold 95,478 shares of the business's stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $1.22, for a transaction totalling $116,483.16. Following the completion of the sale, the chief operating officer now directly owns 574,037 shares of the company's stock, valued at $700,325.14. Learn More on Michel Dahan's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 354,755 shares worth more than $378,207.89. The most recent insider tranaction occured on May, 25th when SVP Nicole R Hadas sold 63,186 shares worth more than $77,086.92. Insiders at Akebia Therapeutics own 3.8% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 5/25/2023.

Michel Dahan Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2023	Sell	95,478	$1.22	$116,483.16	574,037
3/1/2023	Sell	20,412	$0.88	$17,962.56	269,515
2/28/2022	Sell	6,555	$2.15	$14,093.25
4/1/2021	Sell	1,211	$3.40	$4,117.40
2/28/2020	Sell	6,972	$8.70	$60,656.40	211,932
10/2/2017	Sell	1,398	$19.64	$27,456.72
9/28/2017	Sell	5,000	$19.30	$96,500.00	97,224
8/15/2017	Sell	5,000	$15.00	$75,000.00	102,224
4/4/2016	Sell	1,401	$9.41	$13,183.41	74,956

Michel Dahan Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Today's Range

Now: $1.30

$1.21

$1.32

50 Day Range

MA: $0.88

$0.51

$1.43

2 Week Range

Now: $1.30

$0.24

$1.63

Volume

2,814,454 shs

Average Volume

2,014,453 shs

Market Capitalization

$241.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Passive Income Powerhouse Unveiled: The Ultimate Play!

From The Oxford Club | Ad

>>>

Michel Dahan Biography and Net Worth

What is Michel Dahan's net worth?

What is Michel Dahan's salary?

How do I contact Michel Dahan?

Has Michel Dahan been buying or selling shares of Akebia Therapeutics?

Who are Akebia Therapeutics' active insiders?

Are insiders buying or selling shares of Akebia Therapeutics?